Anna Beutler

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

Annals of the Rheumatic Diseases · 2005 · 550 citations

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety…

Arthritis & Rheumatism · 2009 · Last of 12 authors · 480 citations